Felycin-CA1 is the first FDA conditionally approved, once weekly drug for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy or HCM. Felycin-CA1 is formulated specifically for cats in small tablet sizes available in different doses (0.4mg, 1.2mg, and 2.4mg).
Sirolimus
Do not use Felycin®-CA1 in cats with diabetes mellitus. Discontinue immediately if a cat receiving Felycin-CA1 is diagnosed with diabetes mellitus. Do not administer in cats with pre-existing liver disease. The use of Felycin-CA1 in cats with viral disease like feline viral rhinotracheitis has not been evaluated. The safety and effectiveness of Felycin-CA1 has not been evaluated in cats with other cardiomyopathy phenotypes, in cats receiving beta blockers or corticosteroids, in cats with kidney disease, hyperthyroidism, or other significant systemic disease. The effectiveness of Felycin-CA1 has not been evaluated in sexually intact cats, therefore, should not be used in animals intended for breeding. The most frequently observed adverse reactions in cats treated with Felycin-CA1 were cardiovascular in nature, relating to the progression of HCM, and included arrhythmia, congestive heart failure, syncope, and pericardial effusion. Other adverse reactions observed were lethargy, vomiting, diarrhea, and inappetence. Not for human use. Keep out of reach of children. Contact a physician in case of accidental ingestion by humans. Pregnant and breastfeeding women should avoid contact with Felycin-CA1. People with known hypersensitivity to sirolimus should administer Felycin-CA1 with caution..
See full Prescribing Information.Consult your veterinarian and follow your pet's prescription for specific dosing instructions for your pet. Store at controlled room temperature 20–25°C (68–77°F), excursions permitted between 15-30°C (59-86°F). Felycin-CA1 may be administered orally with or without food.